Publications

Authorship and/or medical writing was provided by Medical Affairs 360.

RGI-2001 for the Prophylaxis of Acute Graft-Versus-Host Disease Following Allogeneic HCT. 2025.

RGI-2001 with CNI-based prophylaxis demonstrates better acute GVHD-Free survival following myeloablative allo-HCT without increase relapse: comparison of a multi-center phase 2b study with a contemporaneous CIBMTR cohort. American Society of Transplantation and Cellular Therapy Annual meeting. 2024. Abstract 34. Vol 30 (2) S29.

Risk Factors for Increased Initial Hospital Length of Stay and 30-Day Readmissions in Patients with Relapsed/Refractory Large B-Cell Lymphoma Treated with Chimeric Antigen Receptor T-Cell Therapy at an Academic Cancer Center. ISPOR Poster Presentation 2024

Efficacy and Safety of the addition of RGI-2001 to tacrolimus and methotrexate for acute GVHD prevention in myeloablative HSCT using HLA-matched donors. EBMT Annual meeting, Paris 2023. Poster 869.

Efficacy of the addition of RGI-2001 to tacrolimus and methotrexate for acute GVHD prevention in myeloablative HSCT using HLA-matched donors. ASTCT Annual meeting, Orlando, Florida, Poster 326. 2023. 29(2):S248-S249.

Outcomes of Chimeric Antigen Receptor (CAR) T-Cell Therapy in Patients with Large B-Cell Lymphoma (LBCL): A Single-Institution Experience. Cancers (Basel). 2023;15(18):4671.

Efficacy and Safety of Naloxegol in Patients with Chronic Non-Cancer Pain Who Experience Opioid-Induced Constipation: A Pooled Analysis of Two Global, Randomized Controlled Studies. J Pain Res. 2023;16:2943-2953.

Development of a new travellers' diarrhoea clinical severity classification and its utility in confirming rifamycin-SV efficacy. J Travel Med. 2023;30(6).

RGI-2001 Infusion for Prevention of Acute GVHD after Allogeneic Hematopoietic Cell Transplantation. ASH 64th Annual meeting, New Orleans Oral presentation. Blood (2022) 140 (S1)1877-1878.

Pharmacokinetics and Macrophage Inhibitory Cytokine-1 (MIC-1) pharmacodynamics of the murine double minute 2 (MDM2) Inhibitor, Navtemadlin (KRT-232) in fed and fasted healthy subject (2021) Clin Pharmacol Drug Dev. 2022 11(5):640-653.

Phase I concentration-QTc and cardiac safety analysis of the MDM2 antagonist KRT-232 in patients with advanced solid tumors, multiple myeloma, or acute myeloid leukemia" Clin Pharmacol Drug Dev. 2021. 10(8):918-926.

Pharmacokinetics and safety of KRN7000 following Intravenous Infusion of RGI-2001 in Allogeneic Transplant Patients. ASH Oral presentation. Blood (2020) 136 (S1):15-16.

Increased Foxp3+Helios+ regulatory T cells and decreased acute graft-versus-host disease after allogeneic bone marrow transplantation in patients receiving sirolimus and RGI-2001, an activator of invariant natural killer T cells.Biology of Blood and Marrow Transplantation Vol 23(4)625-634. 2017.

Safety and Tolerability of Ibrutinib in the treatment of previously treated Chronic Lymphocytic Leukemia. Poster presentation at Pan Pacific Lymphoma Conference June 2014.

Safety and Tolerability of Ibrutinib in the treatment of previously treated Mantle Cell Lymphoma. Poster presentation at Pan Pacific Lymphoma Conference June 2014.

Pharmacokinetics and Safety of Ibrutinib with Concomitant Use of CYP3A inhibitors in Patients with B-Cell Malignancies. Annual Meeting American College of Clinical Pharmacology 2014. Abstract 2-57-2000233.

A 9-year evaluation of temporal trends in alosetron postmarketing safety under the risk management program. Therap Adv Gastroenterol. 2013.6(5):344-357.

Changes in Kidney Function and Renal Adverse Events in Clinical Trials Comparing Exenatide Once Weekly and Exenatide Twice Daily. Poster presentation at European Association for the Study of Diabetes (EASD) 47th Annual Meeting; Lisbon, Portugal; September 12-16, 2011. Abstract 823.

Effect of Exenatide on kidney function and adverse events in clinical trials. Poster presentation at 2011 American Diabetes Association, San Diego, California.

Safety and Tolerability of Exenatide Once Weekly Pooled Summary of 1095 Patients From DURATION-1, 2 and 3. Poster Presentation at 2011 German Diabetes Association, Lepizig, Germany.

Safety and Tolerability of Exenatide Once Weekly Pooled Summary of 1095 Patients From DURATION-1, 2 and 3. Oral Presentation on June 26, 2010 American Diabetes Association, Orlando, Florida.

The Risk Management Program (RiskMAP) is Effective in Mitigating Serious Outcomes of Ischemic Colitis and Complications of Constipation with Marketed Use of Alosetron since Reintroduction. Presentation American College of Gastroenterology. 2008, October 2-8. Orlando Florida. Poster #693.

Review of immediate-release omeprazole for the treatment of gastric acid-related disorders. Expert Opin Pharmacother. 2005. 6(14):2501-10.

Advances in proton pump inhibitor therapy: An immediate-release formulation of omeprazole. P & T. December 2005.

Oesophageal pH monitoring--technologies, interpretation and correlation with clinical outcomes. Aliment Pharmacol Ther. 2005. 22(S3): 2-9.

The unmet needs in delayed-release proton-pump inhibitor therapy in 2005. Aliment Pharmacol Ther. 2005. 22 (S3):10-19.

Putting immediate-release proton-pump inhibitors into clinical practice--improving nocturnal acid control and avoiding the possible complications of excessive acid exposure. Aliment Pharmacol Ther. 2005. 22(S3):31-38.

Alternative approaches to the long-term management of GERD. Aliment Pharmacol Ther. 2005. 22(s3):39-44.

Prevention of stress-related mucosal bleeding with proton-pump inhibitors. Aliment Pharmacol Ther. 2005. 22(S3):45-52.

The role of antisecretory therapy in the management of non-variceal upper gastrointestinal bleeding. Aliment Pharmacol Ther. 2005:22(S3):53-58.

Immediate-release proton-pump inhibitor therapy--potential advantages. Aliment Pharmacol Ther. 2005. 22(S3):25-30.